- Stocks
- Pharma & Healthcare
- Roopa Ind
Roopa Ind share price
NSE: ROOPAINDPharma & HealthcareChemicals
Roopa Ind at a glance
With a market capitalisation of ₹38 Cr, it ranks 3246th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Chemicals.
Its return on equity was 11.6% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹30 Cr (+1.0% year on year) and net profit −₹1 Cr (−440.5%), on a standalone basis. Promoters held 48.03% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹38 CrRank 3246 on NSE
- Price to book
- 2.3×FY25
- EPS (TTM)
- ₹0.13to Q4 FY26
- ROE
- 11.6%FY25
- ROCE
- 21.6%FY25
- Debt to equity
- 1.9FY25
- Net profit margin
- 1.7%FY25
- Book value / share
- ₹22.24FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Roopa Ind quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹35 Cr | ₹26 Cr | ₹31 Cr | ₹30 Cr | ₹35 Cr | ₹29 Cr | ₹34 Cr | ₹30 Cr |
| Revenue YoY | +130.8% | +81.0% | +59.7% | +35.1% | +1.6% | +12.2% | +9.1% | +1.0% |
| Net profit | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | −₹1 Cr |
| Net profit YoY | +42.1% | −3.3% | +181.5% | −8.7% | +3.7% | −20.7% | +1.3% | −440.5% |
| Net margin | 0.8% | 2.3% | 2.5% | 1.4% | 0.8% | 1.6% | 2.3% | −4.7% |
| EPS | ₹0.35 | ₹0.74 | ₹0.97 | ₹0.51 | ₹0.36 | ₹0.59 | ₹0.98 | −₹1.80 |
Roopa Ind financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹28 Cr | ₹27 Cr | ₹51 Cr | ₹76 Cr | ₹70 Cr | ₹121 Cr |
| Operating profit | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr |
| Net profit | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr |
| EPS (₹) | ₹0.48 | ₹0.98 | ₹1.30 | ₹1.73 | ₹1.95 | ₹2.57 |
| Cash from operations | ₹2 Cr | −₹1 Cr | ₹2 Cr | ₹9 Cr | −₹3 Cr | −₹7 Cr |
| Total debt | ₹7 Cr | ₹8 Cr | ₹4 Cr | ₹2 Cr | ₹5 Cr | ₹7 Cr |
| Shareholders' equity | ₹11 Cr | ₹12 Cr | ₹13 Cr | ₹14 Cr | ₹15 Cr | ₹17 Cr |
Roopa Ind shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 48.03% | 48.03% | 48.03% | 48.03% | 48.03% | 48.03% |
| Foreign institutions | 0.25% | 0.25% | 0.25% | 0.25% | 0.25% | 0.25% |
| Non-institutions | 51.71% | 51.71% | 51.71% | 51.71% | 51.71% | 51.71% |
Roopa Ind vs peers
The listed Pharma & Healthcare companies nearest to Roopa Ind by market capitalisation.
Ask anything about Roopa Ind
Pivot answers on the live chart with evidence you can check, and tests strategies against ROOPAIND's own history. Try: “Why has ROOPAIND moved over the last three months?” · “Backtest a 50-day moving-average crossover on ROOPAIND over five years” · “Compare ROOPAIND with SANDUPHQ on margins and valuation”
Frequently asked questions about Roopa Ind
What is the market cap of Roopa Ind?
Roopa Ind's market capitalisation is ₹38 Cr (₹38 Cr) at the 22 Oct 2026 close, ranking 3246th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Roopa Ind?
Return on equity was 11.6% in FY25 and return on capital employed was 21.6% in FY25 (standalone figures).
Is Roopa Ind a debt-free company?
No. Roopa Ind's debt-to-equity ratio was 1.9 in FY25, with total debt of ₹7 Cr.
What were Roopa Ind's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Roopa Ind reported revenue of ₹30 Cr, +1.0% year on year, and net profit of −₹1 Cr, −440.5% year on year.
What is the shareholding pattern of Roopa Ind?
As of 30 Jun 2026: promoters 48.03%, foreign institutions 0.25%, non-institutions 51.71%.
Who are Roopa Ind's competitors?
The listed Pharma & Healthcare companies closest to Roopa Ind by market cap are Sandu Pharma, Medicamen Organ, Lasa Supergenerics, JFL Life Scienc, Chandra Bhagat and Sharma East Ind.
Is Roopa Ind a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Roopa Ind's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ROOPAIND against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with R · all NSE stocks · this page as text